Cite
Voortman MM, Greiner P, Moser D, et al. The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(3):2055217318800810doi: 10.1177/2055217318800810.
Voortman, M. M., Greiner, P., Moser, D., Stradner, M. H., Graninger, W., Moser, A., Haditsch, B., Enzinger, C., Fuchs, S., Fazekas, F., Fessler, J., & Khalil, M. (2018). The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Multiple sclerosis journal - experimental, translational and clinical, 4(3), 2055217318800810. https://doi.org/10.1177/2055217318800810
Voortman, Margarete Maria, et al. "The effect of disease modifying therapies on CD62L expression in multiple sclerosis." Multiple sclerosis journal - experimental, translational and clinical vol. 4,3 (2018): 2055217318800810. doi: https://doi.org/10.1177/2055217318800810
Voortman MM, Greiner P, Moser D, Stradner MH, Graninger W, Moser A, Haditsch B, Enzinger C, Fuchs S, Fazekas F, Fessler J, Khalil M. The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018 Sep 20;4(3):2055217318800810. doi: 10.1177/2055217318800810. eCollection 2018. PMID: 30263146; PMCID: PMC6149021.
Copy
Download .nbib